Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Fact Sheet
Oct 13, 2022
| Erica Klinger
How to Talk to Voters About the High Cost of Medicines and Ways to Lower Them
Press Release
Oct 3, 2022
| Susan Reilly
AAM Statement on the Centers for Medicare & Medicaid Services’ Implementation of Medicare Part B Payment Changes for Biosimilars
Blog
Oct 3, 2022
| Monét Stanford
Generics & Biosimilars Continue to Reward Patients, Employers and Taxpayers
Blog
Sep 29, 2022
| Erica Klinger
October Can Now Afford to do More to Support Her Mental Health
Press Release
Sep 21, 2022
| Susan Reilly
Generic and Biosimilar Drugs Generate A Record $373 Billion For America’s Patients and Healthcare System in 2021
Report
Sep 21, 2022
| Erica Klinger
Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report
Press Release
Sep 15, 2022
| Susan Reilly
AAM Statement: New Study Shows Formulary Abuses Force Patients to Pay More for Generic Drugs Even as the Prices of Those Drugs Go Down
Blog
Sep 15, 2022
| Model B
2022 Report
Blog
Sep 6, 2022
| Craig Burton
Explosive Growth in Drug Discount Cards is a Symptom of a Broken System
Video
Aug 23, 2022
| Erica Klinger
October's Story – Savings from Generic Medicines
Press Release
Aug 7, 2022
| Allen Goldberg
AAM Statement on Senate Passage of Inflation Reduction Act
Blog
Jul 28, 2022
| Dan Leonard
AAM All Access Podcast: Medicare Drug Price Negotiation is Bad for Patients
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action